Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Float Short %

0.26

Margin Of Safety %

Put/Call OI Ratio

0.01

EPS Next Q Diff

-0.05

EPS Last/This Y

-0.27

EPS This/Next Y

0.12

Price

1.33

Target Price

7

Analyst Recom

1

Performance Q

-4.9

Relative Volume

0.16

Beta

0.43

Ticker: MNOV




21 items of 1

DateSymbolLastP/C OIP/C VolTotal OI
2025-07-25MNOV1.460.030.0068
2025-07-28MNOV1.4670.030.0069
2025-07-29MNOV1.320.030.0069
2025-07-30MNOV1.360.030.0069
2025-07-31MNOV1.310.030.0069
2025-08-01MNOV1.40.030.0069
2025-08-04MNOV1.350.030.0069
2025-08-05MNOV1.370.020.00118
2025-08-06MNOV1.35070.010.00167
2025-08-07MNOV1.350.010.00167
2025-08-08MNOV1.340.010.00167
2025-08-11MNOV1.33930.010.00198
2025-08-12MNOV1.310.010.00198
2025-08-13MNOV1.27930.010.00198
2025-08-14MNOV1.28970.010.00198
2025-08-15MNOV1.330.010.00223
2025-08-18MNOV1.3150.010.00258
2025-08-19MNOV1.3050.010.00335
2025-08-20MNOV1.320.010.00335
2025-08-21MNOV1.30.010.00335
2025-08-22MNOV1.320.010.00335
DateSymbolLastP/C OIP/C VolTotal OI
21 items Current Page1 of 1




21 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-07-25MNOV1.46- - -0.50
2025-07-28MNOV1.48- - -0.50
2025-07-29MNOV1.33- - -0.50
2025-07-30MNOV1.35- - -0.50
2025-07-31MNOV1.33- - -0.50
2025-08-01MNOV1.43- - -0.50
2025-08-04MNOV1.35- - -0.50
2025-08-05MNOV1.36- - -0.50
2025-08-06MNOV1.36- - -0.50
2025-08-07MNOV1.37- - -0.50
2025-08-08MNOV1.35- - -0.50
2025-08-11MNOV1.34- - -0.50
2025-08-12MNOV1.30- - -0.50
2025-08-13MNOV1.27- - -0.50
2025-08-14MNOV1.29- - -0.50
2025-08-15MNOV1.33- - -0.50
2025-08-18MNOV1.31- - -0.50
2025-08-19MNOV1.30- - -0.50
2025-08-20MNOV1.32- - -0.50
2025-08-21MNOV1.30- - -0.50
2025-08-22MNOV1.33- - -0.50
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
21 items Current Page1 of 1




21 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-07-25MNOV0.00-0.550.27
2025-07-28MNOV0.00-0.550.27
2025-07-29MNOV0.00-0.550.27
2025-07-30MNOV0.00-0.550.27
2025-07-31MNOV0.00-0.550.27
2025-08-01MNOV0.00-0.550.27
2025-08-04MNOV0.00-0.550.27
2025-08-05MNOV0.00-0.550.27
2025-08-06MNOV0.00-0.550.27
2025-08-07MNOV0.00-0.550.27
2025-08-08MNOV0.00-0.550.27
2025-08-11MNOV0.00-0.550.27
2025-08-12MNOV0.00-0.550.26
2025-08-13MNOV0.00-0.550.26
2025-08-14MNOV0.00-0.550.26
2025-08-15MNOV0.00-0.550.26
2025-08-18MNOV0.00-1.480.26
2025-08-19MNOV0.00-1.480.26
2025-08-20MNOV0.00-1.480.26
2025-08-21MNOV0.00-1.480.26
2025-08-22MNOV0.00-1.480.26
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
21 items Current Page1 of 1

Last Quarter Act. EPS

-0.07

Avg. EPS Est. Current Quarter

-0.12

Avg. EPS Est. Next Quarter

-0.12

Insider Transactions

Institutional Transactions

-1.48

Beta

0.43

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

22

Growth Score

24

Sentiment Score

61

Actual DrawDown %

87.7

Max Drawdown 5-Year %

-87.1

Target Price

7

P/E

Forward P/E

PEG

P/S

495.14

P/B

1.37

P/Free Cash Flow

EPS

-0.24

Average EPS Est. Cur. Y​

-0.5

EPS Next Y. (Est.)

-0.38

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-8775.8

Relative Volume

0.16

Return on Equity vs Sector %

-49.9

Return on Equity vs Industry %

-37

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

MediciNova, Inc.
Sector: Healthcare
Industry: Biotechnology
Employees: 13
MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. The company develops MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent in Phase 2b/3 clinical trial for treating neurological and other disorders, such as progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction, as well as prevention of acute respiratory distress syndrome, and long COVID. It is also developing MN-001 (tipelukast), an orally bioavailable small molecule compound in Phase 2 clinical trial to treat fibrotic and other metabolic disorders, including nonalcoholic fatty liver disease and hypertriglycedemia. The company has a license agreement with Kyorin Pharmaceuticals for the development and commercialization of MN-166 and MN-001. MediciNova, Inc. was incorporated in 2000 and is headquartered in La Jolla, California.
stock quote shares MNOV – Medicinova Inc Stock Price stock today
news today MNOV – Medicinova Inc stock forecast ,stock prediction 2023 2024 2025
marketwatch MNOV – Medicinova Inc yahoo finance google finance
stock history MNOV – Medicinova Inc invest stock market
stock prices MNOV premarket after hours
ticker MNOV fair value insiders trading